Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, and PwC Belgium have announced a collaboration aimed at improving equitable and sustainable access to Advanced Therapy Medicinal Products (ATMPs). The initiative will launch with a flagship event in Brussels, bringing together key leaders and stakeholders to tackle barriers limiting patient access to cell and gene therapies.

PwC Belgium contributes expertise in healthcare systems and a network of public and private stakeholders, while Terumo BCT provides technological innovation and operational insights in cell and gene therapy. Together, the collaboration will address the full value chain, including manufacturing, logistics, pricing, reimbursement, and patient pathways.

Veerle D’Haenens, general manager, Global Therapy Innovations at Terumo BCT, said: “By joining forces with PwC Belgium, we are building a platform for meaningful change. This collaboration aims to move beyond discussion and toward concrete, system-level solutions that ensure more patients can access the therapies they need, starting in Europe, where the need is urgent.”

Jan Debaere, partner, Health Industries at PwC Belgium, added: “Our shared vision is to align stakeholders across the care ecosystem in a more agile, integrated approach. This is the beginning of what we hope to be a long-term commitment to unlocking access for patients, starting in Europe and expanding from there.”

Despite advances in ATMPs such as CAR-T and gene therapies, access in Europe remains limited, with only 20–30% of eligible patients receiving treatment. Barriers include constrained treatment capacity, fragmented funding and reimbursement systems, complex logistics, and limited awareness in underserved areas.

The first milestone of the collaboration will be the event “Unlocking patient access to advanced cell therapies”, scheduled for 11 December 2025 at PwC Belgium’s headquarters in Diegem, Brussels. The event will feature TED-style talks and a high-level panel discussion exploring investment models, innovations in manufacturing and logistics, market access strategies, cross-border patient access, and real-world evidence generation.

The collaboration also aims to form a multi-stakeholder ATMP access consortium in early 2026 to coordinate actions, share best practices, and support pilot programs to improve ATMP accessibility across markets.

D’Haenens said: “We hope this is the beginning of meaningful action. Our aim is to evolve this collaboration into a global movement to ensure cell and gene therapies reach the patients who need them, wherever they are.”